Novartis' Sandoz division has filed its biosimilar of Humira in the US, aiming to take a share of its multi-billion dollar revenues once its patent expires. The generics and biosimilars arm of ...

Out of the 14 Humira biosimilars projected to reach the US market in 2023, only six are high concentration. Amgen’s Amjevita, the first Humira biosimilar to launch, is a low-concentration ...

Rheumatoid arthritis drugs fight pain and prevent joint damage. See a full list of RA medications, including NSAIDs, DMARDs, immunosuppressants, and others.

Rheumatoid arthritis (RA) is an autoimmune disease that causes joint pain and inflammation. The condition is chronic, and there’s no cure. However, in recent years, new treatment options have ...